CR1: Complement receptor type 1
Membrane immune adherence receptor that plays a critical role in the capture and clearance of complement-opsonized pathogens by erythrocytes and monocytes/macrophages.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on CR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Mirococept | Phase 2 | — | Protein or peptide | InhibitorComplement receptor type 1 inhibitor | 0 |
- Alzheimer disease0.59
- Dementia0.51
- Late-onset Alzheimers disease0.46
- Neurodegenerative disease0.33
- Splenomegaly0.21
- Chronic intestinal vascular insufficiency0.15
- Polyarticular arthritis0.12
- Hypothyroidism0.12
- Anxiety0.12
- Systemic lupus erythematosus0.11
- Neoplasm0.11
- Hepatocellular carcinoma0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713643, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P17927, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets